Glenmark Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Glenmark Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 28 Products, $205.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Glenmark Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 28 Products, $205.5M Trade | TransData Nexus

Glenmark Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $205.5M Total Trade · DGFT Verified

Glenmark Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $205.5M across 28 products in 14 therapeutic categories. Based on 6,184 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rosuvastatin ($44.3M), Omeprazole ($26.7M), Gabapentin ($26.5M).

Glenmark Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Glenmark Pharmaceuticals Limited pharmaceutical export portfolio — 28 products across 14 therapeutic categories. Source: Indian Customs (DGFT).

Who is Glenmark Pharmaceuticals Limited? — Company Overview & Market Position

Glenmark Pharmaceuticals Limited, established in 1977 by Gracias Saldanha, is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacturing, and marketing of generic drugs, specialty medicines, and over-the-counter (OTC) products. Glenmark's therapeutic focus areas include respiratory, dermatology, and oncology. As of 2025, the company reported revenues of $1.6 billion, with a workforce of approximately 15,800 employees. Glenmark's stock is publicly traded on the National Stock Exchange of India under the ticker symbol GLENMARK.

What Does Glenmark Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Rosuvastatin$44.3M 2Omeprazole$26.7M

Product Portfolio — Top 28 by Export Value

Glenmark Pharmaceuticals Limited exports 28 pharmaceutical products across 14 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rosuvastatin	Cardiovascular	$44.3M	951	9.6%	3
2	Omeprazole	Gastrointestinal	$26.7M	636	4.2%	6
3	Gabapentin	CNS & Psychiatric	$26.5M	530	3.1%	4
4	Ondansetron	Gastrointestinal	$15.9M	635	13.2%	2
5	Naproxen	Analgesics & Antipyretics	$14.1M	303	10.5%	3
6	Telmisartan	Cardiovascular	$9.3M	532	0.1%	6
7	Atovaquone	Antimalarial & Antiparasitic	$9.3M	185	0.9%	2
8	Verapamil	Cardiovascular	$9.1M	184	8.1%	4
9	Carvedilol	Cardiovascular	$8.4M	257	8.6%	4
10	Salbutamol	Respiratory	$5.7M	298	3.9%	2
11	Pravastatin	Cardiovascular	$5.6M	112	18.0%	2
12	Fluconazole	Antifungals	$5.0M	191	5.5%	4
13	Clindamycin	Antibiotics	$4.7M	199	5.2%	5
14	Clotrimazole	Antifungals	$4.5M	428	4.8%	6
15	Cetirizine	Antihistamines & Allergy	$2.9M	115	1.6%	15
16	Tacrolimus	Immunosuppressants	$2.9M	74	1.0%	12
17	Metronidazole	Advanced Antibiotics	$2.4M	131	1.2%	11
18	Indomethacin	Analgesics & Antipyretics	$2.2M	129	16.8%	2
19	Theophylline	Respiratory	$1.6M	60	10.2%	4
20	Proguanil	Antimalarial & Antiparasitic	$993.6K	31	0.1%	2
21	Bromhexine	Respiratory & OTC	$595.1K	31	3.7%	7
22	Guaifenesin	Respiratory & OTC	$594.8K	30	2.2%	8
23	Nitroglycerin	Cardiovascular	$532.6K	11	3.6%	6
24	Salmeterol	Respiratory	$526.5K	40	0.7%	7
25	Budesonide	Respiratory	$489.4K	15	0.3%	11
26	Acyclovir	Antivirals	$330.3K	41	0.3%	15
27	Sirolimus	Immunosuppressants	$214.5K	32	1.4%	8
28	Bortezomib	Advanced Oncology	$150.0K	3	0.7%	8

Glenmark Pharmaceuticals Limited exports 28 pharmaceutical products across 14 therapeutic categories with a total export value of $205.5M. The top category is Cardiovascular (37.6% of portfolio), followed by Gastrointestinal (20.7%), indicating a concentrated portfolio with the top 5 products accounting for 62.0% of total export value.

Glenmark Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Glenmark operates a network of manufacturing facilities across multiple continents, ensuring a robust global supply chain. In India, the company has plants in Goa, Baddi, Nalagarh, Sikkim, Nashik, Indore, and Aurangabad. Internationally, Glenmark's manufacturing presence includes facilities in Monroe, North Carolina, USA; Buenos Aires, Argentina; and Vysoke Myto, Czech Republic. These facilities are equipped to produce a diverse range of pharmaceutical products, including complex injectables, biologics, oral solids, liquids, and topical formulations.

3Key Leadership

Glenn Saldanha serves as the Chairman and Managing Director of Glenmark Pharmaceuticals Limited. Under his leadership, the company has expanded its global footprint and diversified its product portfolio. Anurag Mantri holds the position of Chief Financial Officer, overseeing the company's financial strategies and operations. Other key executives include Ulhas R. Dhuppad, President and Head of Global Pharmaceutical Development, and Indrajit Bose, President and Chief Quality Officer, who play pivotal roles in driving Glenmark's research and development initiatives and ensuring product quality standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Glenmark Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Glenmark Pharmaceuticals Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the United States, the company has FDA-registered facilities and has received approvals for multiple Abbreviated New Drug Applications (ANDAs), facilitating the marketing of generic drugs. Glenmark's products are also available in the European Union and the United Kingdom, adhering to the stringent regulatory standards set by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The company's compliance with Good Manufacturing Practices (GMP) ensures the safety and efficacy of its products in these markets. In Australia, Glenmark's products are registered with the Therapeutic Goods Administration (TGA), and in Japan, the company has obtained approvals from the Pharmaceuticals and Medical Devices Agency (PMDA), enabling access to these key pharmaceutical markets.

2Emerging Markets

Glenmark Pharmaceuticals Limited has strategically expanded its footprint in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to the World Health Organization's (WHO) prequalification program has facilitated the registration and acceptance of its products in these markets, ensuring compliance with international quality standards. This commitment has enabled Glenmark to address the healthcare needs of diverse populations by providing access to affordable and high-quality medicines.

Glenmark Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Glenmark Pharmaceuticals Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), enabling the company to market its products in the United States. The company has received approvals for multiple Abbreviated New Drug Applications (ANDAs), facilitating the introduction of generic drugs to the U.S. market. However, in April 2019, the FDA issued a warning letter to Glenmark's Baddi facility in Himachal Pradesh, India, citing violations of current Good Manufacturing Practice (CGMP) regulations. The warning letter, dated October 3, 2019, highlighted concerns regarding the facility's manufacturing processes and quality control measures. Glenmark has since taken corrective actions to address these issues and ensure compliance with FDA standards.

2WHO & EU GMP

Glenmark Pharmaceuticals Limited's manufacturing facilities adhere to the World Health Organization's (WHO) Good Manufacturing Practices (GMP), ensuring the production of high-quality pharmaceutical products. The company's commitment to quality is further demonstrated by its compliance with the European Union's GMP standards, which are enforced by the European Medicines Agency (EMA). These certifications affirm Glenmark's dedication to maintaining stringent quality control measures across its global manufacturing operations.

Glenmark Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Glenmark Pharmaceuticals Limited operates in a highly competitive global pharmaceutical market, facing competition from both multinational corporations and regional players. In the generic drug segment, the company competes with firms such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, which have established strong market presences. In the specialty medicines and OTC segments, Glenmark faces competition from companies like Novartis, Pfizer, and Merck, which offer a diverse range of therapeutic products. Glenmark's focus on research and development, along with its strategic geographic diversification, positions it to effectively compete in these overlapping categories.

2Key Differentiators

Glenmark Pharmaceuticals Limited distinguishes itself through its robust research and development capabilities, focusing on innovative drug discovery and the development of specialty products. The company's therapeutic emphasis on respiratory, dermatology, and oncology areas addresses significant unmet medical needs. Glenmark's global manufacturing footprint, with facilities across multiple continents, enables efficient production and distribution of its products. Additionally, the company's commitment to quality, as evidenced by its adherence to international GMP standards, reinforces its reputation as a reliable pharmaceutical supplier.

Strategic Position

Buyer Due Diligence Brief — Evaluating Glenmark Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Glenmark Pharmaceuticals Limited has demonstrated a consistent track record in the pharmaceutical industry, with a total export value of $205.5 million USD and 6,184 shipments across 28 products in 14 therapeutic categories. The company's top five exported products—Rosuvastatin, Omeprazole, Gabapentin, Ondansetron, and Naproxen—account for 62% of its export portfolio, indicating a focused product strategy. Glenmark's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA) and comply with international Good Manufacturing Practices (GMP), ensuring the reliability and quality of its products.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Glenmark Pharmaceuticals Limited

How many pharmaceutical products does Glenmark Pharmaceuticals Limited export from India?

Glenmark Pharmaceuticals Limited exports 28 pharmaceutical products across 14 therapeutic categories. The top exports are Rosuvastatin ($44.3M), Omeprazole ($26.7M), Gabapentin ($26.5M), Ondansetron ($15.9M), Naproxen ($14.1M). Total export value is $205.5M.

What is Glenmark Pharmaceuticals Limited's total pharmaceutical export value?

Glenmark Pharmaceuticals Limited's total pharmaceutical export value is $205.5M, based on 6,184 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Glenmark Pharmaceuticals Limited cover?

Glenmark Pharmaceuticals Limited exports across 14 therapeutic categories. The largest are Cardiovascular (37.6%, 6 products), Gastrointestinal (20.7%, 2 products), CNS & Psychiatric (12.9%, 1 products).

Get Full Glenmark Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.